Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results

Table 5 Analysis of MFI and C1q-fixing ability changes in PE-IVIG-RTX group

	Immunodominant DSA specificity	Pre PE-IVIG-RTX (n = 9)		Post PE-IVIG-RTX (n = 8)
		MFI	C1q-fixing	MFI	C1q-fixing
Patient 1	DPw3	13400	No	8200	Yes
Patient 2	DQ9	3000	No	10300	No
Patient 3	A24	9800	Yes	21200	No
Patient 4	DR4	2700	No	0	No
Patient 5	B35	10300	No	2500	No
Patient 6	DQ5	7000	Yes	0	No
Patient 7	DR53	15000	Yes	24000	Yes
Patient 8	DQ7	24400	Yes	9000	Yes
Patient 9	DR51	7400	No	3400	No
Median (min-max)		9800 (2700-24400)1	4/92	8200 (0-24000)1	3/92

¹P = 0.767 for difference in pre- and post-PE-IVIG-RTX MFI;

²P = 1 for difference in pre- and post-PE-IVIG-RTX C1q-fixing ability.